Gilead Sciences (GILD) Net Income towards Common Stockholders (QoQ) (2009 - 2026)
Gilead Sciences (GILD) Net Income towards Common Stockholders (QoQ) (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
-20.06% |
| Dec 31, 2025 |
-17.17% |
| Sep 30, 2025 |
55.63% |
| Jun 30, 2025 |
49.13% |
| Mar 31, 2025 |
-26.21% |
| Dec 31, 2024 |
42.22% |
| Sep 30, 2024 |
-22.41% |
| Jun 30, 2024 |
138.72% |
| Mar 31, 2024 |
-394.56% |
| Dec 31, 2023 |
-34.81% |
| Sep 30, 2023 |
109.05% |
| Jun 30, 2023 |
5.59% |
| Mar 31, 2023 |
-39.74% |
| Dec 31, 2022 |
-8.57% |
| Sep 30, 2022 |
57.36% |
| Jun 30, 2022 |
9,358.33% |
| Mar 31, 2022 |
-96.81% |
| Dec 31, 2021 |
-85.46% |
| Sep 30, 2021 |
71.26% |
| Jun 30, 2021 |
-11.70% |
